As of Tuesday September 8, 2026, the FDA has issued no proposed rule, no Federal Register notice, and no interim enforcement policy following the July 23-24, 2026 Pharmacy Compounding Advisory Committee (PCAC) 5-3 vote recommending six of seven candidate peptides — BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon — for inclusion on the Section 503A Bulk Drug Substances List; emideltide (DSIP) was rejected. Forty-six days have passed since the meeting ended on July 24. Center for Drug Evaluation and Research warning-letter activity to compounding pharmacies has remained elevated through Q3 2026, and no acting-FDA-commissioner statement has updated the industry timeline. The February 2027 PCAC meeting to consider cathelicidin (LL-37), GHK-Cu, dihexa acetate, melanotan II, and PEG-MGF remains scheduled. Nominated FDA Commissioner Dr. Heidi Overton (August 19, 2026) continues to await Senate confirmation with Kyle Diamantas leading the agency in the interim. Formal FDA rulemaking to translate the PCAC recommendation into a proposed rule and then a final rule typically runs 12 to 24 months from PCAC vote; the interval of 46 days is within the normal window but longer than industry advocates had modeled at the meeting.
As of Sunday September 6, 2026, the FDA has issued no proposed rule, no Federal Register notice, and no interim enforcement policy following the July 23-24, 2026 Pharmacy Compounding Advisory Committee (PCAC) vote to recommend six peptides — BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon — for inclusion on the Section 503A Bulk Drug Substances List. The regulatory silence has now lasted 44 days since the meeting ended on July 24, and compounding pharmacies continue to operate in the gray zone that began with the April 16, 2026 removal of 12 peptides from Category 2. Center for Drug Evaluation and Research warning-letter activity to compounding pharmacies remained elevated through Q3 2026. The February 2027 PCAC meeting to consider cathelicidin (LL-37), GHK-Cu, dihexa acetate, melanotan II, and pegylated mechano growth factor (PEG-MGF) remains scheduled. Dr. Heidi Overton (nominated FDA Commissioner August 19, 2026) continues to await Senate confirmation. Formal FDA rulemaking to translate the July PCAC recommendation into a proposed rule and then a final rule typically runs 12 to 24 months from PCAC vote; the interval of just over six weeks is within the normal window but longer than industry advocates had modeled.
As of Saturday September 5, 2026, the FDA has issued no proposed rule, no Federal Register notice, and no interim enforcement policy following the July 23-24, 2026 Pharmacy Compounding Advisory Committee (PCAC) vote to recommend six peptides — BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon — for inclusion on the Section 503A Bulk Drug Substances List. The regulatory silence has now extended six weeks past the vote and continues to leave compounding pharmacies operating in the gray zone that began with the April 16, 2026 removal of 12 peptides from Category 2. Center for Drug Evaluation and Research warning-letter activity to compounding pharmacies has remained elevated through Q3 2026. The February 2027 PCAC meeting to consider cathelicidin (LL-37), GHK-Cu, dihexa acetate, melanotan II, and pegylated mechano growth factor (PEG-MGF) remains scheduled. Dr. Heidi Overton (nominated FDA Commissioner August 19, 2026) continues to await Senate confirmation with acting Commissioner Kyle Diamantas leading the agency through the interim.
As of Thursday September 3, 2026, the FDA has issued no proposed rule, no Federal Register notice, and no interim enforcement policy following the July 23-24, 2026 Pharmacy Compounding Advisory Committee (PCAC) vote to recommend six peptides — BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon — for inclusion on the Section 503A Bulk Drug Substances List. The regulatory silence extends the gray zone that began with the April 16, 2026 removal of 12 peptides from Category 2 and continues to leave compounding pharmacies operating under enforcement risk. CDER warning-letter activity to compounding pharmacies remained elevated through Q3 2026 versus prior years. The February 2027 PCAC meeting to consider cathelicidin (LL-37), GHK-Cu, dihexa acetate, melanotan II, and pegylated mechano growth factor (PEG-MGF) remains scheduled; formal FDA rulemaking to translate PCAC recommendations into a proposed rule typically runs 6 to 18 months. The FDA Commissioner nomination of Dr. Heidi Overton continues to await Senate confirmation, with acting Commissioner Kyle Diamantas leading the agency through the interim.
President Trump announced Wednesday August 19, 2026 the formal nomination of Dr. Heidi Overton, a physician who currently works as deputy assistant to the president for domestic policy and formerly chief policy officer at America First Policy Institute, to serve as the next commissioner of the U.S. Food and Drug Administration. If confirmed by the U.S. Senate, Overton would take over from Kyle Diamantas (JD), who has served as acting commissioner since May 2026 following the departure of Marty Makary. Overton holds an MD from the University of New Mexico and a PhD in clinical investigation from Johns Hopkins Bloomberg School of Public Health, and served in the first Trump administration in the Office of American Innovation and Domestic Policy Council. She is Trump's third choice for the position after former Rep. Brad Wenstrup (R-Ohio) and acting Commissioner Diamantas both declined. The nomination matters for peptide-industry readers because the FDA rulemaking to translate the July 23-24 PCAC 6-peptide 503A recommendation (BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon) into a proposed rule (and eventually a final rule) will run through Overton's tenure if she is confirmed; the February 2027 PCAC meeting on cathelicidin, GHK-Cu, dihexa acetate, melanotan II, and PEG-MGF falls entirely within the window.